An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination
| Autor: | Jinchao Zhang, Yaling Gan, Yongxiang Zhao, Hong Tan, Ningqiang Gong, Xianlei Li, Chi Ma, Shizhu Chen, Yufei Wang, Zhang Jimei, Xing-Jie Liang, Fangzhou Li, Qiankun Ni, Yongchao Wang, Caiwen Ou, Jinjin Wang, Yuxuan Zhang, Yuan Yuan, Junge Chen, Xiaoxuan Liu, Guangchao Qing |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Dendrimers
Porphyrins Light Science medicine.medical_treatment General Physics and Astronomy Cancer immunotherapy Cancer Vaccines General Biochemistry Genetics and Molecular Biology Article Mice Immune system Adjuvants Immunologic In vivo Antigens Neoplasm Dendrimer Cell Line Tumor Neoplasms medicine Animals Humans Adjuvants Neoplasm Metastasis Hypoxia Mice Inbred BALB C Multidisciplinary Chlorophyllides Chemistry Vaccination Cancer General Chemistry Dendritic Cells medicine.disease Mice Inbred C57BL Antitussive Agents Cancer research NIH 3T3 Cells Nanoparticles Tumour immunology Immunotherapy Signal transduction Neoplasm Recurrence Local Transcriptome Adjuvant |
| Zdroj: | Nature Communications Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021) |
| ISSN: | 2041-1723 |
| Popis: | Immunological adjuvants are essential for successful cancer vaccination. However, traditional adjuvants have some limitations, such as lack of controllability and induction of systemic toxicity, which restrict their broad application. Here, we present a light-activable immunological adjuvant (LIA), which is composed of a hypoxia-responsive amphiphilic dendrimer nanoparticle loaded with chlorin e6. Under irradiation with near-infrared light, the LIA not only induces tumour cell lysis and tumour antigen release, but also promotes the structural transformation of 2-nitroimidazole containing dendrimer to 2-aminoimidazole containing dendrimer which can activate dendritic cells via the Toll-like receptor 7-mediated signaling pathway. The LIA efficiently inhibits both primary and abscopal tumour growth and induces strong antigen-specific immune memory effect to prevent tumour metastasis and recurrence in vivo. Furthermore, LIA localizes the immunological adjuvant effect at the tumour site. We demonstrate this light-activable immunological adjuvant offers a safe and potent platform for in situ cancer vaccination. Immunological adjuvants are a crucial component of cancer vaccines. Here the authors design a light-activable immunological adjuvant, based on hypoxia-responsive amphiphilic dendrimer nanoparticles loaded with a photodynamic agent, promoting anti-tumor immune responses in preclinical cancer models. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|